1 Concerning Trend for AbbVie Investors to Keep an Eye On
https://www.fool.com/investing/2024/01/03/1-concerning-trend-for-abbvie-investors-to-keep-an/?source=iedfolrf0000001
Jan 03, 2024 - Is AbbVie a good stock for dividend investors to own?
0
2 Biotech Stocks You Can Buy and Hold for the Next Decade
https://www.fool.com/investing/2024/01/02/2-biotech-stocks-you-can-buy-and-hold-for-the-next/?source=iedfolrf0000001
Jan 02, 2024 - The types of innovative drugs these companies develop are always in high demand.
0
Here's How Much a $1000 Investment in AbbVie Made 10 Years Ago Would Be Worth Today
https://www.zacks.com/stock/news/2204045/here-s-how-much-a-1000-investment-in-abbvie-made-10-years-ago-would-be-worth-today?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2204045
Jan 01, 2024 - Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
0
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
https://www.zacks.com/stock/news/2202697/astrazeneca-azn-set-to-acquire-gracell-for-1-2-billion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202697
Dec 27, 2023 - AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.
0
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
https://www.zacks.com/stock/news/2201667/bristol-myers-bmy-to-buy-karuna-therapeutics-for-14b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201667
Dec 22, 2023 - Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.
0
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199324
Dec 18, 2023 - Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
0
AbbVie (ABBV) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2199022/abbvie-abbv-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2199022
Dec 15, 2023 - In the latest trading session, AbbVie (ABBV) closed at $154.04, marking a -0.54% move from the previous day.
0
Here's How Much You'd Have If You Invested $1000 in AbbVie a Decade Ago
https://www.zacks.com/stock/news/2197856/here-s-how-much-you-d-have-if-you-invested-1000-in-abbvie-a-decade-ago?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2197856
Dec 14, 2023 - Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
0
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors
https://www.fool.com/investing/2023/12/12/abbvie-just-followed-pfizers-big-move-heres-what/?source=iedfolrf0000001
Dec 12, 2023 - It's making a major acquisition to beef up a key area of its pipeline.
0
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
0